We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


osteolabs Provides Further Validation for Use of OsteoTest

Credit: Pixabay

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "osteolabs Provides Further Validation for Use of OsteoTest"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

osteolabs GmbH has announced further validation and clinical evidence for the use of OsteoTest for the early detection of bone loss. OsteoTest represents a new type of predictive test for osteoporosis that provides early insights into the bone mineral balance of the human body using a simple urine or blood sample. So far, such a diagnosis currently requires the use of X-ray technology (DXA), which is invasive, less sensitive and represents a potential radiation risk for the patient. In this context, osteolabs, together with the University Medical Center Kiel, were able to show in a recent study of 100 women that the OsteoTest can better predict fractures caused by bone atrophy and importantly, less invasively than the DXA method currently used (Study from CRC GmbH Kiel, GEO-Osteo-2016, NCT02967978, publication in preparation).

In addition, clinical physicians from the Catholic University of Leuven in Belgium successfully applied the OsteoTest in a recent study to verify the side effects of an androgen deprivation therapy as part of a prostate therapy for men. The latter also confirms the usefulness of checking OsteoTest for predicting bone calcium-related loss even for men.

Bone loss is also a serious side effect of kidney dysfunction, although difficult to predict with current diagnostics. A recent clinical trial in collaboration with the Great Ormond Street Hospital for Children of University College London and the GEOMAR Helmholtz Center in Kiel has shown that OsteoTest also qualifies as a biomarker for early renal dysfunction. The researchers show a highly significant dependence of the OsteoTest results on the status of the renal dysfunction (publication in preparation).

“We are very satisfied with the recent clinical results for OsteoTest for early detection of bone loss in women but also in men”, said Prof. Dr. Eisenhauer, Scientific Lead for osteolabs and GEOMAR scientist. “Initial results are also very exciting for our test to serve as a diagnostic tool for the tubular functionality of the kidney, with further studies required for full clinical validation."